New Biomarker Predicts Immunotherapy Benefit in Advanced Prostate Cancer, finds study Dr. Kamal Kant Kohli28 May 2026 9:00 PM ISTResearchers with the James P. Allison Institute at The University of Texas MD Anderson Cancer Center have discovered a new gene expression signature...
Intralesional nivolumab may be effective against precancerous oral lesions: Study Dr. Kamal Kant Kohli30 April 2026 8:15 PM ISTInjecting nivolumab (Opdivo) directly into precancerous oral lesions led to reduction in lesion size and allowed some patients to avoid surgery,...
Dual Immunotherapy With Liver-Directed Therapy Improves Outcomes in Metastatic Uveal Melanoma: The Lancet Medha Baranwal9 March 2026 8:00 PM ISTNetherlands: Researchers have found in a new study that adding the dual checkpoint inhibitors ipilimumab and nivolumab to percutaneous hepatic...
Bristol Myers Approaches SC to Halt Zydus' Biosimilar Nivolumab Sale Parthika Patel30 Jan 2026 7:35 PM ISTNew Delhi: Bristol Myers Squibb has approached the Supreme Court of India, seeking to restrain Zydus Lifesciences from manufacturing and selling its...
Delhi HC Clears Zydus' Cancer Drug ZRC-3276 Despite BMS Patent Claim Susmita Roy12 Jan 2026 11:42 PM ISTNew Delhi: In a judgment of far-reaching significance for India's pharmaceutical and patent jurisprudence, the Delhi High Court has allowed Zydus...
Biocon Biologics Eyes USD 75 Billion Oncology Market, Adds 3 New Biosimilar Drugs Parthika Patel7 Jan 2026 4:37 PM ISTThese products are among the largest oncology biologics expected to lose exclusivity over the next five years.
CDSCO Panel Clears Bristol Myers' Yervoy for Two New Cancer Indications Susmita Roy28 Nov 2025 9:09 PM ISTNew Delhi: In a significant regulatory development for cancer care in India, the Subject Expert Committee functioning under the Central Drugs Standard...
SEC Asks Enzene Biosciences to Revise Phase III Trial Protocol for Nivolumab Biosimilar Parthika Patel12 Oct 2025 10:30 AM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has asked Enzene Biosciences Ltd to revise...
Delhi HC Bars Zydus From Launching Cancer Drug Nivolumab Biosimilar Till 2026 Farhat Nasim23 July 2025 4:45 PM ISTNew Delhi: In a major setback to Zydus Lifesciences, the Delhi High Court has restrained the company from launching its proposed biosimilar of the...
Bristol Myers Squibb bags European Commission nod for Subcutaneous formulation of Opdivo across multiple solid tumor indications Ruchika Sharma29 May 2025 10:00 AM ISTPrinceton: Bristol Myers Squibb has received approval from the European Commission (EC) for a new Opdivo (nivolumab) formulation...
Bristol Myers Squibb bags European Commission approval for Opdivo combo in lung cancer treatment Ruchika Sharma18 May 2025 11:45 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved the perioperative regimen of neoadjuvant...
Bristol Myers Squibb receives positive EMA Committee opinion for Perioperative Opdivo plus Chemo in Resectable Non-Small Cell Lung Cancer plus PD-L1 Ruchika Sharma30 March 2025 12:15 PM ISTBristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
